Taken together, our findings suggest that dopamine receptor D1- and D2-agonists might not constitute a promising therapeutic approach for peripherally inducing BAT thermogenesis for treatment of obesity or associated metabolic disorders. Here, DIO2 is linked to metabolic disease.